KPV reconstitution calculator
Type in a vial size, the diluent volume you added, and a dose figure — the calculator below converts those three numbers into a concentration, a draw volume, and a syringe reading. It performs the same arithmetic as our tirzepatide and sermorelin calculators. What it cannot do, for KPV specifically, is check that arithmetic against an FDA-approved product's own label, because no such label — or product — exists. Read why below before you use it.
There is no approved product or dosing standard behind this calculator
KPV — short for Lysine-Proline-Valine, the three amino acids in its name — is a tripeptide fragment of the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). It has never had an FDA-approved drug product of its own: a direct check against DailyMed, the National Library of Medicine's official archive of FDA-approved drug labeling, returns zero results for "KPV." Most of the published research behind it is anti-inflammatory signaling work — rodent colitis models and skin-inflammation studies — not the kind of human dosing evidence a label is built from, and it is a chemically distinct molecule from the other peptides on this calculator, not a variant of BPC-157 or TB-500.
Its compounding status is also unsettled, and has moved recently: KPV sat on FDA's interim Section 503A Category 2 list (bulk substances presenting significant safety risks that pharmacies should not compound) from 2023 until April 15, 2026, when FDA removed it — along with eleven other peptides, including TB-500, BPC-157 and injectable GHK-Cu — because the nomination behind that listing was withdrawn, effective April 22, 2026. That removal does not make compounding KPV legal; it only lifts the "significant safety risk" flag and leaves it outside every category while further review continues. That review has already happened: at FDA's Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026, the committee voted 8-6-1 to recommend adding KPV to the 503A bulks list, alongside similar recommendations for BPC-157 and TB-500. A committee recommendation is not final agency action — as of this page's last review, FDA had not yet formally added KPV to the list.
What the tool below actually does is narrower than that context might suggest: it takes the vial size, diluent volume, and dose you type in and returns the concentration and draw volume that arithmetic implies — nothing more. It cannot confirm that a particular vial is what its label claims, that the dose you enter is appropriate for you, that it is currently legal for a pharmacy to have compounded it, or that the product you drew that number from came from a legitimate source. A correct-looking syringe reading is not evidence that any of those things are true.
Sources: DailyMed structured-product-label search for "KPV" (zero results), FDA's April 15, 2026 removal of KPV from the interim Section 503A Category 2 bulk drug substances list, and FDA's July 23-24, 2026 Pharmacy Compounding Advisory Committee vote on KPV, all independently checked 2026-08-02. View the DailyMed search.
Where to go next
- Compare against the compounds this calculator supports that do have an FDA-approved reference product, on the calculator hub.
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.